TGFBR1 and cancer: Targeting TGF-β signaling in cancer has moved into clinical trials with an inhibitor of the kinase activity of the TGF-β receptor type I (TGFBR1/ALK5), Vactosertib, now in several trials, including a phase 2 trial in NSCLC (NCT04515979).